ORIC-944 is a small molecule commercialized by ORIC Pharmaceuticals, with a lead...
Rhenium (186Re) Obisbemeda is a small molecule commercialized by Plus Therapeuti...
As part of a first-line treatment for patients with inoperable pancreatic adenoc...
Novartis has paid out $1 billion upfront for worldwide rights to PTC Therapeutic...
The results from the Phase III trial found the LDL-C treatment to be well tolera...
The EMA has validated Chiesi Global Rare Diseases and Protalix’s submission to u...
An improved price discount and new evidence from Santhera has changed NICE’s tun...
The respiratory syncytial virus (RSV) prophylaxis market across the eight major ...
Seres Therapeutics has received US FDA breakthrough therapy designation for its ...
The US FDA has accepted a submission from GSK to review a new indication of Nuca...
Lilly’s investment and the UK government’s strategic support for life sciences a...
The prevailing treatment paradigm for newly diagnosed multiple myeloma (NDMM) pa...
InCarda Therapeutics has announced the appointment of Dr Myles Greenberg as its ...
While 88.1% of patients completed one cycle, patient adherence beyond the fourth...
The US FDA has granted priority review to AstraZeneca's sBLA for Imfinzi (durval...
The US FDA has granted RMAT designation to Affimed and Artiva Biotherapeutics’ c...
